Aclaris 制药
ACRS
3.28
-0.21
-6.02%
Aclaris 制药
US · ACRS
#3750 按市值排名
上市于 2015
3.28
-0.21
-6.02%
实时 - 追踪5344个代码 - 心跳于527秒前
· 2026-10-16 20:02
✦ 量化股权信号 计算方式说明
减持
- 机构持股总比例下降了1.6个百分点。
机构持股
- 机构持股比例
- 84.13% -1.63pp
- 机构数量
- 173
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
VC/PE Fund31.22%
Mutual Fund26.64%
Hedge Fund24.78%
Individual/Insider2.21%
Public Company0.78%
Private Company0.40%
Insurance Company0.17%
Government Pension Fund0.10%
Other13.68%
主要股东 截至 2026-06-30
RA Capital Management, L.P.
8.64% · 12.72M 股
BML Capital Management, LLC
8.14% · 11.98M 股
BlackRock
6.82% · 10.04M 股
Deep Track Capital, LP
6.35% · 9.35M 股
Frazier Life Sciences Management, LP
5.93% · 8.73M 股
Vanguard Capital Management, LLC
4.57% · 6.73M 股
Vivo Capital, LLC
4.55% · 6.69M 股
Rock Springs Capital Management LP
2.94% · 4.33M 股
Adage Capital Management, L.P.
2.77% · 4.07M 股
Decheng Capital LLC
2.75% · 4.04M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 40次买入 · 10次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Neal Walker | Chairperson | 1.05% |
| Anand Mehra | Independent Director | 0.49% |
| Joseph Monahan | Chief Scientific Officer | 0.18% |
| James Loerop | Chief Business Officer | 0.13% |
| Kevin Balthaser | Chief Financial Officer | 0.13% |
| Christopher Molineaux | Lead Independent Director | 0.05% |
| Hugh M. Davis | President | 0.03% |
| William Humphries | Independent Director | 0.03% |
| Douglas Manion | Chief Executive Officer | 0.03% |
| Maxine Gowen | Independent Director | 0.02% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-07-31 | Roland Kolbeck | Chief Scientific Officer | Derivative Exercise and Sale | -12,385 | $5.20 |
| 2026-07-31 | Roland Kolbeck | Chief Scientific Officer | Derivative Exercise and Retained | +23,990 | -- |
| 2026-06-04 | Vincent Milano | Independent Director | Derivative Exercise and Retained | +11,580 | -- |
| 2026-06-04 | Andrew Schiff | Independent Director | Derivative Exercise and Retained | +11,580 | -- |
| 2026-06-04 | Maxine Gowen | Independent Director | Derivative Exercise and Retained | +11,580 | -- |
| 2026-06-04 | William Humphries | Independent Director | Derivative Exercise and Retained | +11,580 | -- |
| 2026-06-04 | Anand Mehra | Independent Director | Derivative Exercise and Retained | +11,580 | -- |
| 2026-06-04 | Christopher Molineaux | Lead Independent Director | Derivative Exercise and Retained | +11,580 | -- |
| 2026-06-03 | Vincent Milano | Independent Director | Other Derivative Acquisition | +10,987 | -- |
| 2026-06-03 | Vincent Milano | Independent Director | Other Derivative Acquisition | +42,350 | $4.71 |
| 2026-06-03 | Andrew Schiff | Independent Director | Other Derivative Acquisition | +10,987 | -- |
| 2026-06-03 | Andrew Schiff | Independent Director | Other Derivative Acquisition | +42,350 | $4.71 |
| 2026-06-03 | Maxine Gowen | Independent Director | Other Derivative Acquisition | +10,987 | -- |
| 2026-06-03 | Maxine Gowen | Independent Director | Other Derivative Acquisition | +42,350 | $4.71 |
| 2026-06-03 | William Humphries | Independent Director | Other Derivative Acquisition | +10,987 | -- |
| 2026-06-03 | William Humphries | Independent Director | Other Derivative Acquisition | +42,350 | $4.71 |
| 2026-06-03 | Anand Mehra | Independent Director | Other Derivative Acquisition | +10,987 | -- |
| 2026-06-03 | Anand Mehra | Independent Director | Other Derivative Acquisition | +42,350 | $4.71 |
| 2026-06-03 | Christopher Molineaux | Lead Independent Director | Other Derivative Acquisition | +10,987 | -- |
| 2026-06-03 | Christopher Molineaux | Lead Independent Director | Other Derivative Acquisition | +42,350 | $4.71 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 20:02:31 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
Aclaris 制药 讨论区 0 条评论